Germany
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from SIRION Biotech GmbH.
WALTHAM, Mass.–(BUSINESS WIRE)–Jun. 22, 2021– PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) is pleased to announce it has entered into an
agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector-based technologies that drive improved delivery performance
for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.Headquartered in Munich, Germany, privately held SIRION has approximately 50 employees based in Germany, the U.S. and France. The company has established a strong licensing portfolio leveraged by over a dozen major pharmaceutical and biotech players researching more than twenty five diseases and conditions.
This is the News section of the company profile page for SIRION Biotech GmbH on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
